At the news
? NEUTRALIMPACT 4/10 8-K filed Apr 3, 2026 at 16:05 ET
AbbVie updated its 2026 adjusted diluted EPS guidance to $13.96–$14.16, incorporating a $0.41 per share impact from Q1 2026 acquired IPR&D and milestones expense. This follows the company's prior full-year guidance of $14.37–$14.57, which excluded such expenses.
- AbbVie issued updated 2026 full-year adjusted diluted EPS guidance of $13.96–$14.16, down from prior range of $14.37–$14.57
- The reduction reflects a $0.41 per share impact from acquired IPR&D and milestones expense incurred in Q1 2026
- The company does not forecast future IPR&D or milestones expenses due to uncertainty in timing and occurrence
- This filing provides preliminary estimates; final results are subject to closing procedures
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access